We are employing a novel dual-target approach to reprogram the CoREST complex, which plays a critical role in the regulation and proliferation of blood cells and immune pathways relevant to myeloproliferative disease.
Our lead program is JBI-802, a first-in-class, orally available, dual CoREST (LSD1 + HDAC6) inhibitor under clinical investigation for essential thrombocythemia (ET) and other serious blood disorders.
